VTL vs. ZNTL, NLTX, CKPT, SLN, MNPR, IFRX, PBYI, CRBP, BMEA, and VTYX
Should you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Zentalis Pharmaceuticals (ZNTL), Neoleukin Therapeutics (NLTX), Checkpoint Therapeutics (CKPT), Silence Therapeutics (SLN), Monopar Therapeutics (MNPR), InflaRx (IFRX), Puma Biotechnology (PBYI), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), and Ventyx Biosciences (VTYX). These companies are all part of the "medical" sector.
Vital Therapies vs.
Vital Therapies (NASDAQ:VTL) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.
In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Vital Therapies. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 0 mentions for Vital Therapies. Zentalis Pharmaceuticals' average media sentiment score of 0.76 beat Vital Therapies' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Vital Therapies has a beta of 3.51, indicating that its share price is 251% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.
Vital Therapies received 310 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 74.40% of users gave Vital Therapies an outperform vote while only 63.44% of users gave Zentalis Pharmaceuticals an outperform vote.
Zentalis Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 342.48%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Vital Therapies.
15.5% of Vital Therapies shares are owned by institutional investors. 33.9% of Vital Therapies shares are owned by company insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Zentalis Pharmaceuticals' return on equity of -43.91% beat Vital Therapies' return on equity.
Summary
Zentalis Pharmaceuticals beats Vital Therapies on 7 of the 13 factors compared between the two stocks.
Get Vital Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vital Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:VTL) was last updated on 1/22/2025 by MarketBeat.com Staff
